CRP and rheumatoid arthritis: Non-responders or patients with markers of a poor prognosis (occurrence of erosions, rheumatoid factor, or anti–citrullinated protein antibodies, and a baseline Disease Activity Score in 28 joints based on C-reactive protein) should be switched to biologic therapy with the aim of achieving either remission in those with early RA, or LDA in those with established RA.